Kadence Bio
UK - LondonBiotechnology
Focus: Kadence Bio is a UK-based biotech company focused on developing novel treatments for premature ejaculation and oncology indications. The company operates as a pre-revenue stage biotech with a single Phase 2 program in active development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Kadence Bio
AI assessmentNot HiringNo open roles listed right now. Follow Kadence Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
KH-001 ODT
Premature EjaculationClinical Trials (1)
NCT07434271Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)
Phase 2Help build intelligence for Kadence Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.